EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Evolving Role of Genomics in Colorectal Cancer

A M Berner, N Murugaesu

Clinical Oncology · 2025-01 · 37 · 103661

DOI: 10.1016/j.clon.2024.10.033 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Oncology, 2025-01. Verfasst von A M Berner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6AU, UK. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Genomics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 75% of colorectal cancers (CRCs) harbour an identifiable driver mutation, 5% of which are heritable. These drivers have recognised implications for prognosis and therapy selection. In addition, potential germline mutations require investigations to inform testing of relatives, as well as surveillance for other malignancies. With increasing numbers of targeted drugs being approved, judicious testing is required to ensure sufficient tumour sample is available for testing and at the right point in the cancer pathway. Liquid biopsy with circulating tumour DNA (ctDNA) in the blood presents an exciting adjunct to tumour tissue testing for molecular drivers, as well as escalation and de-escalation of therapy. Here, we review the most frequent molecular alterations in CRC, how genomic testing should be integrated into the treatment pathway for CRC, and sources of further education.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsGenomicsHumansMutationBiomarkers, TumorCirculating Tumor DNA

Stichwörter der Autor:innen

Circulating tumour DNAGeneticsGenomicsGenomics tumour advisory boardHereditary cancerNext generation sequencing

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6AU, UK.
  • Guy's & St Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK; Genomics England, 1 Canada Square, London E14 5AB, UK. Electronic address: n.murugaesu@nhs.net.

Förderung

  • National Institute for Health and Care Research

Zitieren

APA

Berner, A. M., & Murugaesu, N. (2025). The Evolving Role of Genomics in Colorectal Cancer. Clinical Oncology, 37, 103661. https://doi.org/10.1016/j.clon.2024.10.033

Vancouver

Berner AM, Murugaesu N. The Evolving Role of Genomics in Colorectal Cancer. Clinical Oncology. 2025;37:103661. doi:10.1016/j.clon.2024.10.033

BibTeX
@article{Berner2025,
  author = {Berner, A M and Murugaesu, N},
  title = {The Evolving Role of Genomics in Colorectal Cancer},
  journal = {Clinical Oncology},
  year = {2025},
  volume = {37},
  pages = {103661},
  doi = {10.1016/j.clon.2024.10.033}
}
Kostenlos starten →